SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

Di Filippo M.;Ferraro D.;Ragonese P.;Prosperini L.;Maniscalco G. T.;Gallo A.;Cavalla P.;Lorefice L.;Nociti V.;Di Sabatino E.;Clerico M.;Guaschino C.;Radaelli M.;Fantozzi R.;Buttari F.;Laroni A.;Gajofatto A.;Calabrese M.;Malucchi S.;Paolicelli D.;De Luca G.;Tomassini V.;Lanzillo R.;Moccia M.;Solaro C.;Cocco E.;Gasperini C.;Tortorella C.

2024-01-01

---

Abstract

Background: COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks associated with the third booster dose in pwMS, such as vaccine-triggered disease exacerbations, are still scarce. Objective: To investigate whether the administration of a third booster dose of mRNA COVID-19 vaccines was associated with an increased risk of short-term disease reactivation in a large cohort of pwMS. Methods: We retrospectively selected 1265 pwMS who received a third booster dose of an mRNA COVID-19 vaccine. Demographic and clinical data were collected, including the presence, number and characteristics of relapses in the 60 days prior to and after the third booster dose. Results: In the selected cohort, the relapse rate in the two months after administration of the third booster dose of mRNA COVID-19 vaccines did not increase when compared with the prior two months. Indeed, the percentage of pwMS experiencing relapses in the 60 days following the administration of the third booster dose was 2.1%, similar to the percentage recorded in 60 days prior to vaccination, which was 1.9%. Conclusions: The third booster dose of mRNA COVID-19 vaccines appeared to be safe for pwMS.